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 The most common genetic abnormalities of ependymomas involve the chromosome 22 where there
is the oncosuppressor gene neurofibromin 2 (NF2). NF2 mutations are primarily encountered in
spinal lesions. In contrast, NF2 alterations do not seem related to tumor grade. We studied the NF2
expression through a real-time polymerase chain reaction in 25 pediatric anaplastic ependymomas.
We compared the NF2 expression in neoplastic and non-neoplastic tissues, in supratentorial and in-
fratentorial ependymomas and in primitive and non-primitive tumors (recurrences and metastases).
Statistical analysis did not prove significant differences. Our results suggest that NF2 alterations
are not typical of intracranial anaplastic ependymomas.
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INTRODUCTION
Ependymomas account for 3–9% of neuroepithelial tumors and are the
third most common brain tumor diagnosed in children after pilocytic as-
trocytoma and medulloblastoma. They arise from ependymal cells lining
the ventricles and the spinal canal. Little is known of the etiopathogene-
sis of ependymomas. An increased incidence of ependymomas, particularly
spinal ependymomas, has been reported in patients affected by neurofibro-
matosis type 2 (NF2) syndrome. Actually, the most common genetic abnor-
malities of ependymomas involve the chromosome 22 where there is the
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oncosuppressor gene neurofibromin 2 (NF2). NF2 gene mutations are re-
sponsible for NF2 syndrome, which is associated with a high incidence of
tumors (i.e., schwannomas, meningiomas, and ependymomas) [10, 16, 19].
The NF2 gene encodes the production of merlin (also called schwan-
nomin). Merlin is a member of the proteins 4.1 superfamily. Within the 4.1
superfamily, merlin shares the highest degree of homology with a subgroup
of proteins including ezrin, radixin, and moesin (ERM proteins) that in
polarized cells link the actin of the cytoskeleton to cell membrane glyco-
proteins. The similarity of merlin with the ERM proteins indicates that its
function may be related to those of the ERM proteins: organization of mem-
brane extensions and cell adhesion, membrane traffic, and cell signaling.
Merlin is expressed in a variety of tissues during embryonic development
and in adulthood. In the normal central nervous system, merlin is widely
expressed particularly in glia and neurons [8, 22]. Several experimental
data demonstrated that the merlin over-expression results in a significant
decrease in cell proliferation, reversion of Ras-induced transformation, and
reduced tumor formation in nude mice. On the contrary, the inactivation of
the NF2 gene leads to the development of tumors through the loss of contact-
dependent inhibition of growth. In addition to the tumors that are classically
associated with NF2 syndrome, NF2 mutations may be also found in other
tumors, i.e., mesotheliomas of the lung. Furthermore, merlin expression is
reduced in human malignant gliomas [4–7, 11, 12,14, 17,23, 24].
Approximately 29–38% of ependymomas show monosomy or transloca-
tions on chromosome 22 19 [3]. Among ependymomas, NF2 mutations are
primarily encountered in spinal lesions. In contrast, it has been assumed
that NF2 alterations do not significantly vary with tumor grade [1, 2, 9, 13,
18,20, 21, 25].
In the present work, we studied the NF2 expression through a real-time
polymerase chain reaction (RT-PCR) in a group of 25 pediatric intracranial
anaplastic ependymomas. In addition, we compared the merlin expression
in supratentorial and infratentorial ependymomas and in primitive and non-
primitive tumors (recurrences or metastases).
PATIENTS AND METHODS
Patients
Twenty-five tissue specimens were obtained from 16 consecutive pa-
tients affected by anaplastic ependymomas surgically treated at the Anna
Meyer Pediatric Hospital in which fresh tumoral tissue was available
for the RT-PCR. Eight (50%) were from men and 8 (50%) were from
women. The average age at the time of the first surgery at our institution
was 7 years (range, 1–17). (Table 1) None of the patients had clinical evi-
dence of NF2 syndrome.
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TABLE 1 Clinical Characteristics of the Patients
ID Pz Age Sex Tumor
1 BM 11 M SUPRATENTORIAL RELAPSE
2 12 RELAPSE
3 12 RELAPSE
4 BA 5 M SUPRATENTORIAL RELAPSE
5 6 RELAPSE
6 7 RELAPSE
7 9 RELAPSE
8 CC 1 F INFRATENTORIAL PRIMITIVE
9 FaF 14 F SUPRATENTORIAL RELAPSE
10 15 RELAPSE
11 15 RELAPSE
12 FrF 4 F INFRATENTORIAL PRIMITIVE
13 LM 10 M SUPRATENTORIAL PRIMITIVE
14 MG 1 M INFRATENTORIAL PRIMITIVE
15 1 PRIMITIVE
16 MI 13 M SUPRATENTORIAL RELAPSE
17 13 RELAPSE
18 NT 16 M SUPRATENTORIAL RELAPSE
19 RE 5 F INFRATENTORIAL RELAPSE
20 RA 2 F SUPRATENTORIAL PRIMITIVE
21 SL 2 M INFRATENTORIAL RELAPSE
22 SJ 1 M INFRATENTORIAL PRIMITIVE
23 GF 4 F INFRATENTORIAL RELAPSE
24 VCA 1 F INFRATENTORIAL PRIMITIVE
25 ZFI 17 M CAUDAL SPINAL
CORD
METASTASIS
Abbreviations: ID = identification number; Pz = patient; M = male; F = female.
Methods
Histologic diagnoses were made at the Department of Human Pathology
and Oncology at the University of Florence and were performed according
to the World Health Organization (WHO) criteria [16].
A series of six brain tissues obtained from six patients surgically treated
because of non-neoplastic condition were used as control samples. According
to institutional policies, the use of human tissue for study purposes was
approved through a written informed consent.
From each fresh surgical specimen of anaplastic ependymomas, we se-
lected a fragment macroscopically representative of the tumor. After doing
so, we cut it in half: from one half several 5-µm frozen sections stained
with hematoxylin-eosin (H&E) were obtained to verify the adequacy of the
specimen selected for real-time presence of pathologic tissue only or non-
neoplastic brain parenchyma in cases that we used as control polymerase
chain reaction (PCR) the other half was immersed in ribonucleic acid (RNA)
later (QIAGEN, Valencia, CA), kept overnight at + 4◦C, and finally stored
at −80◦C until analysis.
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Real-Time PCR
The tissue (about 5 mg) was defrosted and cut into small pieces. The
samples were resuspended in 200 µl of nucleic acid purification Lysis solution
(Applied Biosystems, Foster City, CA) and homogenized using tissue Lyser
(Qiagen, Milan, Italy) in microcentrifuge tubes. After proteinase K digestion
(250 µg/ml for 1 h at 50◦C), RNA was isolated using a 6100 Nucleic Acid
Prep Station (Applied Biosystems, Foster City, CA) and successively stored
at −80◦C.
The RNA concentration and purity was quantitated spectrophotometri-
cally by measuring their absorbance at 260 nm and 280 nm. All RNA sam-
ples (200 ng) were reverse transcribed to cDNA using iScript Select cDNA
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) according to the man-
ufacturer’s protocol. In the reverse transcription reaction, negative control
was performed. Real-time quantitative PCR was performed on an ABI PRISM
7000 Sequence Detector System (Applied Biosystems, Foster City, CA). PCR
products for NF2 were detected using gene-specific primers and probes
labeled with reporter day FAM (Assay on Demand, Applied Biosystems).
gAPDH was used as endogenous control gene for normalization.
PCR reactions were carried out in 96-well plate with 20 µl per well using
1x TaqMan Universal PCR Master Mix. After an incubation for 2 min at 50◦C
and 10 min at 95◦C, the reaction continued for 50 cycles at 95◦C for 15 sec
and 60◦C for 1 min.
Results Analysis
At the end of the reaction, the results were evaluated using ABI 7000
PRISM software (Applied Biosystems) and the Ct values were exported to Mi-
crosoft Excel. The 2 −Ct method described by Livak and Schmittgen [15]
was used to calculate fold expression levels of all 25 ependymomas relative
to the average value of the six non-neoplastic specimens, of 17 non-primitive
(16 recurrences and 1 metastasis), anaplastic ependymomas relative to the
average value of the eight primitive anaplastic ependy-momas, and 15 supra-
tentorial tumors relative to the average value of the eight 4th ventricular
ependymomas.
Statistical Analysis
The shift of the expression level of NF2 as estimated through relative
RT-PCR was calculated according to the Kruskal-Wallis test. Data analysis
was performed using the Primit statistical package, Version 3.03 (McGraw-
Hill Inc, Milan, Italy). The AP value ≤ 0.05 was considered to be statistically
significant.
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FIGURE 1 Anaplastic ependymoma (case 1) hypercellularity and numerous mitoses are appreciable.
Hematoxylin-Eosin; original magnification ×200.
RESULTS
Fifteen (60%) anaplastic ependymomas were supratentorial, nine (36%)
were infratentorial, and one (4%) was spinal. Eight (32%) lesions were
primitive tumors, 16 (64%) were recurrences, and one (4%) was a caudal
spinal cord metastasis. (Table 1)
We successfully extracted RNA from all samples. NF2 gene expression
was present in all ependymomas and in all six non-neoplastic brain tissues.
Fifteen (60%) tumor samples expressed the NF2 gene higher than non-
neoplastic tissues (max 0,65 times higher) (Table 2; Figure 2). Eight (53%)
supratentorial ependymomas expressed the NF2 gene lower than infraten-
torial ependymomas (max 0,56 times lower). (Table 3; Figure 3). Ten (59%)
non-primitive lesions (nine recurrences and only one spinal metastasis) ex-
pressed the NF2 gene higher than primitive ependymomas (max 0,71 times
higher) (Table 4; Figure 4).
Statistical analysis did not establish significant differences (P > 0.04)
between non-neoplastic or neoplastic specimens, supra or infratentoria,l
and primitive or non-primitive anaplastic ependymomas.
DISCUSSION
Ependymomas are infrequent tumors of neuroectodermal origin clas-
sifying as World Health Organization (WHO) Grades I, II, and III. Ninety
percent of ependymomas are intracranial and the majority of these arise in
the posterior fossa.
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FIGURE 2 RT-PCR merlin expression in 25 anaplastic ependymomas (reference value: mean merlin
expression in 6 non neoplastic cerebral specimens). The number of the lesions corresponds to the ID
number of Table 1.
TABLE 2 RT-PCR: log RQ in 25 Anaplastic Ependymomas (Reference Value: Mean Merlin Expression
in 6 Non Neoplastic Cerebral Specimens)
ID Pz log RQ
1 BM 0,329284
2 0,652891
3 0,420195
4 BA −0,30619
5 0,254628
6 0,055045
7 −0,27518
8 CC 0,34584
9 FaF 0,186295
10 −0,09788
11 −0,13039
12 FrF 0,382867
13 LM −0,00877
14 MG 0,286237
15 0,518933
16 MI −0,34984
17 −0,52233
18 NT −0,38235
19 RE 0,194121
20 RA 0,058959
21 SL 0,349152
22 SJ −0,60963
23 GF 0,083342
24 VCA −0,91548
25 ZFI 0,054744
Abbreviations: ID = identification number; Pz = patient.
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FIGURE 3 RT-PCR merlin expression in 15 supratentorial anaplastic ependymomas (refer-ence value:
mean merlin expression in 9 infratentorial anaplastic ependymomas). The number of the lesions corre-
sponds to the ID number of Table 1.
The single most important prognostic factor is the extent of tumor re-
section so that ependymoma is considered a “surgical disease.” In fact, the
local relapses determine the majority of adverse outcomes. Nevertheless, it
has been demonstrated that the histological tumor grade is also a predictor
of the clinical behavior. Actually, WHO III anaplastic ependymomas show
an unfavorable outcome [3].
Several molecular alterations have been reported in ependymomas, in-
cluding aberrations involving chromosomes 1, 6, 7, 9, 10, 11, 12, 13, 16,
17, and the NF2 gene on chromosome 22q12 which encodes for merlin
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FIGURE 4 RT-PCR merlin expression in 17 non-primitive anaplastic ependymomas—16 recurrences;
1 caudal spinal cord metastasis (reference value: mean merlin expression in 8 primitive anaplastic
ependymomas). The number of the lesions corresponds to the ID number of Table 1.
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TABLE 3 RT-PCR: log RQ in 15 supratentorial anaplastic ependymomas (refer-ence value: mean
merlin expression in 9 infratentorial anaplastic ependymomas)
ID Pz log RQ
1 BM 0,293263
2 0,616871
3 0,384174
4 BA −0,34221
5 0,218608
6 0,019025
7 −0,3112
9 FaF 0,150274
10 −0,1339
11 −0,16641
13 LM −0,04479
16 MI −0,38586
17 −0,55835
18 NT −0,41837
20 RA 0,022938
Abbreviations: ID = identification number; Pz = patient.
protein [21]. Mutations on the NF2 gene are considered the most frequent
molecular alterations in ependymomas. Nevertheless, the analyses of mu-
tations of the NF2 suppressor gene have yielded conflicting results. It has
been postulated that NF2 mutations with consequent loss of merlin func-
tions are related to spinal ependymomas only. Actually, in the opinion of
some authors, spinal ependymomas could constitute a molecular variant
TABLE 4 RT-PCR: og RQ in 17 non-primitive anaplastic ependymomas—16 recurrences; one caudal
spinal cord metastasis (reference value: mean merlin expression in 8 primitive anaplastic
ependymomas).
ID Pz log RQ
1 BM 0,394994
2 0,718602
3 0,485905
4 BA −0,24048
5 0,320339
6 0,120756
7 −0,20947
9 FaF 0,252005
10 −0,03217
11 −0,06468
16 MI −0,28413
17 −0,45662
18 NT −0,31664
19 RE 0,259832
21 SL 0,414862
23 GF 0,149053
25 ZFI 0,120455
Abbreviations: ID = identification number; Pz = patient.
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of ependymomas characterized by a high incidence of NF2 mutations. In
1994, in a group of 8 ependymomas (2 spinal and 6 intracranial; 4 WHO
Grade II and 2 WHO Grade III) Rubio documented a single NF2 gene base
deletion in a WHO II spinal ependymoma which also had lost the wild-type
allele [20]. In 1996, Birch stated that 5 of 7 spinal ependymomas that he
studied harbored mutations on the NF2 gene resulting in a truncation of
the predicted protein product [2]. In 2002, Alonso stated that 1 anaplastic
WHO III spinal ependymoma of her series of 7 ependimomas (2 spinal and
5 intracranial; 4 WHO Grade II and 3 WHO Grade III) showed mutation of
the NF2 gene [1].
In our study, we compared the merlin expression in anaplastic intracra-
nial ependymomas and in the non-neoplastic brain tissue. The observation
that no significant differences in the merlin expression were found between
ependymomas of our series (24 intracranial and 1 caudal cord metasta-
sis) and non-neoplastic cerebral parenchyma might indirectly support the
hypothesis that NF2 alterations are unusual in intracranial ependymomas
(both infratentorial and supratentorial ependymomas as also evaluated by
comparing their expression).
Furthermore, among ependymomas with NF2 alterations reported in
the literature, there were a number of anaplastic ependymomas. This ob-
servation stimulates us to further exclude the possibility of a grade related
phenomenon. In this regard, we confirm that modifications in the NF2 ex-
pression did not characterize anaplastic ependymomas.
On the other hand, we can also suppose that the alterations in NF2 are
not more frequent in a relapsed lesion than in primary tumors. Indeed,
we did not observe a significant difference in primitive and non-primitive
ependymomas.
In conclusion, although the method of research that we used (evaluation
of the merlin expression through RT-PCR) did not assess NF2 gene aberra-
tions, our results may indirectly provide evidence that NF2 gene mutations
do not play an important role in the aetiology and progression of intracranial
anaplastic ependymomas.
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